Symbols

CHE

Chemed·NYSE

--(--)

CHE fundamentals

CHE Q4 2025 Earnings

Chemed (CHE) released its earnings on Feb 25, 2026: revenue was 639.34M (YoY -0.10%), missed estimates; EPS was 6.42 (YoY -6.00%), missed estimates.

Revenue / YoY

639.34M

-0.10%

EPS / YoY

6.42

-6.00%

Report date

Feb 25, 2026

CHE Earnings Call Summary for Q4,2025

VITAS Turnaround: Florida Medicare Cap resolved, 2026 revenue growth 5.5-6.5%, EBITDA margin 17.5-18%. Short-stay admissions drove Q4 2025 miss but set stage for H2 2026 recovery.
Roto-Rooter Challenges: 2025 revenue decline 3.7%, water restoration write-offs up 57%. 2026 guidance: 3-3.5% revenue growth, 22.5-23% EBITDA margin, driven by centralized billing and commercial expansion.
Shareholder Returns: $2.9B buybacks since 2025, 2026 EPS guidance $23.25-24.25 (+7.8% YoY).

Earnings

EPS

Revenue

Revenue & Expenses

CHE has released its 2025 Q4 earnings report, with revenue of 639.34M, reflecting a YoY change of -0.10%, and net profit of 76.75M, showing a YoY change of -15.02%. The Sankey diagram below clearly presents CHE's revenue sources and cost distribution.

Key Indicators

Chemed (CHE) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Chemed (CHE)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Chemed (CHE)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Chemed (CHE)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown